Amplia uncovers new clue in pancreatic cancer drug trial
The Sydney Morning Herald - Oct 22, 2026
Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.